Truist Financial Corp Sells 36,611 Shares of Sanofi (NASDAQ:SNY)

Truist Financial Corp cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 560,623 shares of the company's stock after selling 36,611 shares during the quarter. Truist Financial Corp's holdings in Sanofi were worth $27,039,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Jennison Associates LLC raised its position in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock worth $82,366,000 after buying an additional 1,424,289 shares during the period. DAVENPORT & Co LLC raised its holdings in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after buying an additional 664,455 shares during the period. JPMorgan Chase & Co. raised its holdings in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, Franklin Resources Inc. raised its holdings in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock worth $208,106,000 after buying an additional 395,744 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SNY has been the topic of several recent analyst reports. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $60.00.

Sanofi Stock Up 0.6 %

Shares of SNY traded up $0.33 during trading hours on Friday, reaching $54.46. The company's stock had a trading volume of 1,424,158 shares, compared to its average volume of 2,301,609. The firm has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $50.95 and a two-hundred day moving average of $52.53.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.